Literature DB >> 12696013

Stability of undiluted and diluted vaccinia-virus vaccine, Dryvax.

Frances K Newman1, Sharon E Frey, Tamara P Blevins, Lihan Yan, Robert B Belshe.   

Abstract

The stability of Dryvax vaccine was examined to determine whether diluted vaccine could be used over an extended period, thereby increasing the number of available doses. Stability parameters that we evaluated include dilution (undiluted, diluted 1:5, and diluted 1:10), diluent (original Dryvax diluent, new Dryvax diluent, and phosphate-buffered saline), and temperature (refrigerator temperature and room temperature). Storage of reconstituted Dryvax vaccine at room temperature, regardless of dilution or diluent, resulted in a significantly greater decrease in titer than did storage at refrigerator temperature. At refrigerator temperature, the decrease in vaccinia-vaccine titer during the first year was not significantly different between the undiluted Dryvax vaccine and either of the 2 diluted forms of Dryvax vaccine, with any of the 3 diluents.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12696013     DOI: 10.1086/374564

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  4 in total

1.  Can vaccinia virus be replaced by MVA virus for testing virucidal activity of chemical disinfectants?

Authors:  Holger F Rabenau; Ingrid Rapp; Jochen Steinmann
Journal:  BMC Infect Dis       Date:  2010-06-23       Impact factor: 3.090

2.  MAVERICC: Marker-free Vaccinia Virus Engineering of Recombinants through in vitro CRISPR/Cas9 Cleavage.

Authors:  Ethan Laudermilch; Kartik Chandran
Journal:  J Mol Biol       Date:  2021-02-24       Impact factor: 5.469

3.  Single-dose replicating poxvirus vector-based RBD vaccine drives robust humoral and T cell immune response against SARS-CoV-2 infection.

Authors:  Stephen Boulton; Joanna Poutou; Nikolas T Martin; Taha Azad; Ragunath Singaravelu; Mathieu J F Crupi; Taylor Jamieson; Xiaohong He; Ricardo Marius; Julia Petryk; Christiano Tanese de Souza; Bradley Austin; Zaid Taha; Jack Whelan; Sarwat T Khan; Adrian Pelin; Reza Rezaei; Abera Surendran; Sarah Tucker; Emily E F Brown; Jaahnavi Dave; Jean-Simon Diallo; Rebecca Auer; Jonathan B Angel; D William Cameron; Jean-Francois Cailhier; Réjean Lapointe; Kyle Potts; Douglas J Mahoney; John C Bell; Carolina S Ilkow
Journal:  Mol Ther       Date:  2021-10-20       Impact factor: 12.910

4.  Surprisingly Effective Priming of CD8+ T Cells by Heat-Inactivated Vaccinia Virus Virions.

Authors:  Sarah Croft; Yik Chun Wong; Stewart A Smith; Inge E A Flesch; David C Tscharke
Journal:  J Virol       Date:  2020-09-29       Impact factor: 5.103

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.